相关实验视频
Updated: May 20, 2025

05:48
Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
6.1K
新兴的粉样蛋白寡合体的生物物理起源和病原性影响
Huayuan Tang1,2, Nicholas Andrikopoulos3, Yuhuan Li3,4
1Department of Engineering Mechanics, Hohai University, Nanjing, 211100, China.
Nature communications
|March 26, 2025
概括
寡合体,而不仅仅是纤维,是阿尔茨海默氏症和帕金森病的关键. 了解这些早期的蛋白质聚合物对于开发有效的粉样蛋白疾病治疗方法至关重要.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 粉样蛋白假设是理解阿尔茨海默氏症和帕金森病的核心.
- 蛋白质聚合,从单体到纤维,驱动神经退行.
- 寡合体代表了蛋白质聚合中的早期,短暂和神经毒性物种.
研究的目的:
- 阐明蛋白质寡合体在粉样蛋白疾病中的作用.
- 探索神经毒性寡合物的形成途径.
- 研究寡合物对神经退行和脑血管功能的影响.
主要方法:
- 通过液-液相分离形成的寡合体的分析.
- 描述β-桶寡合体形成的特征.
- 对寡合体诱导的神经毒性和脑血管效应的评估.
主要成果:
- 确定了由液-液相分离和β-桶形成产生的明显的寡合体结构.
- 证明了这些寡合体对神经退行过程的直接贡献.
- 揭示了寡合体在脑血管干扰中的重要作用.
结论:
- 蛋白质寡合体是粉样蛋白疾病病理学的关键联系点.
- 向寡合体形成和毒性是一个有前途的治疗策略.
- 对寡合物轴的全面理解对于治疗阿尔茨海默氏症和帕金森病至关重要.
更多相关视频
00:15Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
5.9K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.2K
相关概念视频
Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399